Bob Hugin’s time at Celgene
Bob Hugin and his company have helped nearly 300,000 patients access and afford the medicines they needed.
Under Bob Hugin’s leadership, hundreds of thousands of patients were able to access and afford their life-saving medicines, and nearly 90% of patients got their medicines for $50 a month or less.
Under Bob Hugin’s leadership, Celgene invested an industry-leading 40% of their revenues – over $25 billion since 2006 – in research and development to discover revolutionary medicines that saved and extended lives.
While Bob Hugin was CEO, the annual R&D investment increase (36.9%) was 5x the average annual Revlimid price increase (7.5%), the leading anti-cancer treatment developed by Celgene for patients with multiple myeloma.
In 2016 alone, Bob Hugin and Celgene spent $4.5 billion on research, nearly as much as the National Cancer Institute.
In 2017, Bob Hugin and Celgene’s R&D investment was over 45% of revenues, and nearly 15% more than any other top bio-pharmaceutical company.
Bob Hugin and Celgene partnered with over 200 patient organizations to support and advance pro-patient policies, outreach, education and advocacy.
Under Bob Hugin’s leadership, survival rates in multiple myeloma patients more than doubled between 2001 and 2014.
Under Bob Hugin’s leadership, the number of Celgene full-time employees has quadrupled over the last decade, creating thousands of high-quality jobs right here in New Jersey, including more than 2,500 researchers.